Why the study?
The renin-angiotensin system has pleiotropic roles in critical biological processes in lung cancer, motivating an evaluation of whether pathway blockade could serve as adjuvant therapy.
Does renin-angiotensin system blockade serve as an effective adjuvant therapy in lung cancer?
Does renin-angiotensin system blockade serve as an effective adjuvant therapy in lung cancer?
This review highlights the pleiotropic role of the renin-angiotensin system in lung cancer and suggests its blockade may have potential as an adjuvant therapy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for renin-angiotensin system blockade as lung cancer adjuvant; prospective trials needed before clinical consideration.
The mechanistic involvement of the renin-angiotensin system (RAS) reaches beyond cardiovascular physiopathology. Recent knowledge pinpoints a pleiotropic role for this system, particularly in the lung, and mainly through locally regulated alternative molecules and secondary pathways. Angiotensin peptides play a role in cell proliferation, immunoinflammatory response, hypoxia and angiogenesis, which are critical biological processes in lung cancer. This manuscript reviews the literature supporting a role for the renin-angiotensin system in the lung tumor microenvironment and discusses whether blockade of this pathway in clinical settings may serve as an adjuvant therapy in lung cancer.
No takes yet. Share an insight, caveat, or question.
Catarata et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: